Torna al Registre Simple

 

Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary

dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorde Langen, Adrianus
dc.contributor.authorDingemans, Anne-Marie
dc.contributor.authorPless, Miklos
dc.contributor.authorJohnson, Melissa
dc.contributor.authorMAZIERES, JULIEN
dc.contributor.authorMountzios, Giannis
dc.contributor.authorFELIP, ENRIQUETA
dc.date.accessioned2025-04-30T06:45:37Z
dc.date.available2025-04-30T06:45:37Z
dc.date.issued2025
dc.identifier.citationde Langen AJ, Melissa LJ, Julien M, Dingemans AMC, Giannis M, Miklos P, et al. Sotorasib versus docetaxel for previously treated KRAS G12C–mutated non–small–cell lung cancer: a plain language summary. Futur Oncol. 2025;21(9):1033-44.
dc.identifier.issn1744-8301
dc.identifier.urihttp://hdl.handle.net/11351/13017
dc.descriptionMutació; Càncer de pulmó de cèl·lules no petites
dc.description.sponsorshipThis manuscript was funded by Amgen Inc.
dc.language.isoeng
dc.publisherTaylor & Francis
dc.relation.ispartofseriesFuture Oncology;21(9)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectAnomalies cromosòmiques
dc.subjectPulmons - Càncer - Tractament
dc.subjectPulmons - Càncer - Aspectes genètics
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subjectMedicaments antineoplàstics - Ús terapèutic
dc.subject.meshMutation
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Agents
dc.subject.mesh/therapeutic use
dc.subject.meshTreatment Outcome
dc.titleSotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1080/14796694.2025.2474789
dc.subject.decsmutación
dc.subject.decscarcinoma de pulmón de células no pequeñas
dc.subject.decs/farmacoterapia
dc.subject.decsantineoplásicos
dc.subject.decs/uso terapéutico
dc.subject.decsresultado del tratamiento
dc.relation.publishversionhttps://doi.org/10.1080/14796694.2025.2474789
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[de Langen AJ] Netherlands Cancer Institute, Amsterdam, The Netherlands. [Johnson ML] Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, USA. [Mazieres J] Centre Hospitalier Universitaire de Toulouse, Toulouse, France. [Dingemans AMC] Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands. [Mountzios G] Henry Dunant Hospital Center, Athens, Greece. [Pless M] Kantonsspital Winterthur, Winterthur, Switzerland. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid40129223
dc.identifier.wos001451877500001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Portada del document
Name:
sotorasib-versus-docetaxel-pre ...
Grandària:
3.175Mb
Format:
PDF
Description:
Sotorasib versus docetaxel for ...
Visualitza

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple